Swiss National Bank Sells 1,400 Shares of Supernus Pharmaceuticals, Inc. $SUPN

Swiss National Bank reduced its stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 1.3% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 107,000 shares of the specialty pharmaceutical company’s stock after selling 1,400 shares during the period. Swiss National Bank owned approximately 0.19% of Supernus Pharmaceuticals worth $3,504,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently modified their holdings of the company. LPL Financial LLC grew its position in Supernus Pharmaceuticals by 18.9% during the 4th quarter. LPL Financial LLC now owns 12,741 shares of the specialty pharmaceutical company’s stock worth $461,000 after acquiring an additional 2,029 shares during the last quarter. Wells Fargo & Company MN grew its position in Supernus Pharmaceuticals by 14.4% during the 4th quarter. Wells Fargo & Company MN now owns 63,237 shares of the specialty pharmaceutical company’s stock worth $2,287,000 after acquiring an additional 7,961 shares during the last quarter. Envestnet Asset Management Inc. grew its position in Supernus Pharmaceuticals by 6.2% during the 4th quarter. Envestnet Asset Management Inc. now owns 59,970 shares of the specialty pharmaceutical company’s stock worth $2,169,000 after acquiring an additional 3,495 shares during the last quarter. Bank of Montreal Can grew its position in Supernus Pharmaceuticals by 6.6% during the 4th quarter. Bank of Montreal Can now owns 7,595 shares of the specialty pharmaceutical company’s stock worth $275,000 after acquiring an additional 473 shares during the last quarter. Finally, Raymond James Financial Inc. bought a new stake in Supernus Pharmaceuticals during the 4th quarter worth approximately $6,847,000.

Supernus Pharmaceuticals Stock Performance

NASDAQ:SUPN opened at $42.68 on Thursday. The stock’s fifty day moving average price is $34.94 and its two-hundred day moving average price is $33.65. Supernus Pharmaceuticals, Inc. has a 52-week low of $29.16 and a 52-week high of $43.73. The company has a market cap of $2.39 billion, a price-to-earnings ratio of 37.11 and a beta of 0.74.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on SUPN. Cantor Fitzgerald increased their price target on Supernus Pharmaceuticals from $42.00 to $46.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 6th. Wall Street Zen upgraded Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, August 2nd. Two research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $41.00.

Insider Activity

In other news, Director Bethany Sensenig sold 5,369 shares of the stock in a transaction on Thursday, August 14th. The stock was sold at an average price of $42.25, for a total value of $226,840.25. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Frederick M. Hudson sold 7,457 shares of the stock in a transaction on Thursday, August 14th. The shares were sold at an average price of $42.26, for a total value of $315,132.82. Following the completion of the transaction, the director directly owned 46,307 shares in the company, valued at approximately $1,956,933.82. This trade represents a 13.87% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 152,826 shares of company stock valued at $6,424,773 in the last 90 days. 8.80% of the stock is owned by company insiders.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.